BioProNET is a network that focuses on the use of cells and their components (that is, bioprocessing) to produce biologics, which we define as products that are composed of proteins (such as antibodies), peptides, RNA, DNA or vaccines.
Such biologics could be used as therapeutics, for example as biopharmaceuticals or as non-therapeutics, for example in diagnostics, industrial enzymes, for drug screening, and for crystallization and structural studies.
BioProNET’s objectives and goals are to:
- Provide leadership and vision to the UK academic and industrial community in the field of bioprocessing of biologics to usher in new collaborative models that accelerate innovation and deliver change.
- Facilitate the generation of collaborative and cross-disciplinary grant proposals and the subsequent award of major research funding from UK and international sources that ultimately generates outputs of direct benefit to the sector.
- Create an internationally recognised biologics community that is able to harness discoveries in the basic sciences for application to industrial bioprocesses and the supply chain that partners with complementary networks.
- Provide a vehicle for the delivery of proof of concept studies that lead to more competitive, collaborative, cross disciplinary and integrative funding proposals.
- Create an environment that promotes the emergence of new technologies, including synthetic biology, genomics and systems biology to allow for more rapid, flexible, predictable and cost-efficient production of biologics.
- Inspire and develop the next generation of scientists across the breath of disciplines encompassed by the network.
- Provide a mechanism for fostering community interactions and international collaboration allowing the rapid response to research challenges, policy changes, and large research calls.
- Open a route for academics to apply to industrially relevant challenges and consider the societal, environmental, economic and political ramifications of their work.
BioProNET Management Board, Advisory Board and Executive Group
The management board of BioProNET is refreshed annually to ensure that it reflects the interest base of the membership of BioProNET and the strategic vision for the future across the breadth of bioprocessing. We also have an advisory board and an Exective Board.
The current management board are:
Karen Coopman – Loughborough University
Paul Dalby – University College London
Amanda Weiss – NightstaRx
John Liddell – Centre for Process Innovation
Nigel Titchener-Hooker – University College London
Tobias von der Haar – University of Kent
Ray Field – MedImmune
Richard Alldread – Centre for Process Innovation
Tony Hitchcock – Cobra Biologics
Paul Davis – Mologic
We also have an advisory board, headed by Mark Carver from FujiFilm Diosynth Biotechnologies. Other members are:
Peter Levison – Pall Life Sciences
Paul Varley – MedImmune
Carol Marshall – GlaxoSmithKline
Nigel Slater – University of Cambridge
Robert Falconer – University of Sheffield
Dave Brockwell – University of Leeds
Ray Marroitt – Bangor University
David Humphreys – UCB
BioProNET Executive Group
Please feel free to contact us
Mark Smales – Director, University of Kent
+44 (0)1227 823746
Alan Dickson – Co-director, University of Manchester
+44 (0)161 275 5077
Joanne Flannelly – Network Manager, University of Manchester
+44 (0)161 306 0503
Charlotte Harrison – Network Manager, University of Kent
+44 (0)1227 816068